Evidence map›Paper›PMID 16722838›Full record

ReviewBritish journal of clinical pharmacology2006

Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?

Kathleen M Knights, Arduino A Mangoni, John O Miners

Open access · greenAbstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cardiovascular risk, hypertension, and NSAIDs.Current pain and headache reports · 2007
    Review
  10. Cardiovascular risk, hypertension, and NSAIDs.Current rheumatology reports · 2007
    Review
  11. Article
  12. The NSAID roller coaster: more about rofecoxib.British journal of clinical pharmacology · 2006
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kathleen M KnightsDepartment of Clinical Pharmacology, Flinders University, Bedford Park, Adelaide, Australia. kathie.knights@flinders.edu.au
Arduino A Mangoni
John O Miners
Flinders University · AUFlinders Medical Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) have long been known to cause gastrointestinal and renal toxicity. More recently, adverse cardiovascular effects have been associated with the selective COX-2 inhibitors. However, current studies that show an increased cardiovascular risk with non-selective NSAIDs raise the question of the exclusive contribution of COX-2 to this type of toxicity. Aldosterone, a key cardiovascular hormone, can induce deleterious effects, such as myocardial fibrosis and vascular stiffening. Non-selective NSAIDs inhibit the metabolism of aldosterone in vitro by human renal tissue, predicating an increased plasma aldosterone concentration in vivo. The question remains whether inhibition of aldosterone metabolism by non-selective NSAIDs is a casual or causal factor in NSAID-induced cardiovascular toxicity.

Indexed as

AldosteroneAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesHumansMineralocorticoid Receptor AntagonistsRisk FactorsAldosteroneAnti-Inflammatory Agents, Non-SteroidalMineralocorticoid Receptor Antagonists

Identifiers

PMID16722838
PMCPMC1885103
OpenAlexW1982935335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.